- Home
- TCON
as 05-17-2024 4:00pm EST
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | San Diego |
| Market Cap: | 3.3M | IPO Year: | 2015 |
| Target Price: | $60.00 | AVG Volume (30 days): | 271.7K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $14.74 | Next Earning Date: | 05-14-2024 |
| Revenue: | $12,145,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest TRACON Pharmaceuticals Inc. News
TCON Breaking Stock News: Dive into TCON Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
5 days ago
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
GuruFocus.com
5 days ago
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Associated Press Finance
5 days ago
Tracon: Q1 Earnings Snapshot
GlobeNewswire
5 days ago
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
12 days ago
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
GlobeNewswire
a month ago
TRACON Pharmaceuticals Announces Reverse Stock Split
GlobeNewswire
2 months ago
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
Insider Monkey
2 months ago